Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study

Key Points

• The aim is to evaluate the effectiveness of elranatamab versus teclistamab in treating relapsed and refractory multiple myeloma.
• Utilized a propensity score-matched design to minimize bias.
• Analyzed real-world data from multiple myeloma patients.
• Compared treatment outcomes between elranatamab and teclistamab.
• Elranatamab showed improved efficacy compared to teclistamab in the matched cohort.
• Individualized treatment selection is supported by the findings.